Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of XBIO-015 in patients with pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors

Next Previous
X
Search
Trial Profile

Study of XBIO-015 in patients with pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XBIO 015 (Primary)
  • Indications Colorectal cancer; Pancreatic cancer; Solid tumours
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Dec 2024 New trial record
    • 05 Dec 2024 According to a Xenetic Biosciences media release, Under the terms of the Agreement, PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors.
    • 05 Dec 2024 According to a Xenetic Biosciences media release, the company has entered into a Clinical Trial Services Agreement with the Israel-based biotechnology company PeriNess Ltd to advance the Company's development program for its systemic DNase I candidate in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors toward exploratory clinical studies.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top